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Abstract
Background: It is becoming increasingly difficult to keep information about genetic ancestry separate from information
about health, and consumers of genetic ancestry tests are becoming more aware of the potential health risks associated
with particular ancestral lineages. Because some of the proposed associations have received little attention from oversight
agencies and professional genetic associations, scientific developments are currently outpacing governance regimes for
consumer genetic testing.
Main text: We highlight the recent and unremarked upon emergence of biomedical studies linking markers of genetic
ancestry to disease risks, and show that this body of scientific research is becoming part of public discourse connecting
ancestry and health. For instance, data on genome-wide ancestry informative markers are being used to assess health
risks, and we document over 100 biomedical research articles that propose associations between mitochondrial
DNA and Y chromosome markers of genetic ancestry and a wide variety of disease risks. Taking as an example an
association between coronary heart disease and British men belonging to Y chromosome haplogroup I, we show
how this science was translated into mainstream and online media, and how it circulates among consumers of
genetic tests for ancestry. We find wide variations in how the science is interpreted, which suggests the potential
for confusion or misunderstanding.
Conclusion: We recommend that stakeholders involved in creating and using estimates of genetic ancestry
reconsider their policies for communicating with each other and with the public about the health implications
of ancestry information.
Keywords: Direct-to-consumer genetic tests, Genetic ancestry, Disease/Health risk, Regulation, Social implications,
Public understanding
Background
While genetic ancestry tests marketed to consumers do
not currently claim to provide information about disease
risk, it is becoming increasingly difficult to keep infor-
mation about ancestry separate from information about
health. In this article, we consider the recent and unre-
marked upon growth in genetic tests and biomedical
studies linking markers of genetic ancestry to various
diseases and medical conditions. These developments
are becoming part of public discourse connecting ancestry
and health, but because genetic testing companies, over-
sight agencies, and professional genetic associations
have largely treated health and ancestry genetic tests as
independent and distinct, little guidance is available to
help consumers understand and interpret the reported
connections between genetic ancestry and disease risk.
Consequently, when such findings circulate in the pub-
lic realm, consumers learn that there may be health
risks tied to their genetic ancestry even though com-
panies do not report those associations. There is there-
fore potential for confusion or misunderstanding that is
problematic for both consumers and the scientific com-
munity. We argue that the various stakeholders in genetic
ancestry testing need to reconsider what they communi-
cate about the health implications of ancestry information,
both to the public and to each other, in order to effectively
bridge the gap that currently exists in policies and
consumer guidance regarding genetic tests for ancestry
and health.
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The gap between genetic tests for health and
ancestry
Genetic ancestry tests were first marketed directly to
consumers in 2000, for the purpose of reconstructing
genealogies and investigating personal genetic heritage.
They quickly became the most popular of all consumer
genetic testing services, and more than three million in-
dividuals have reportedly purchased these tests to date
[1, 2]. Over the last 15 years, companies [3], regulators
[4] and professional scientific associations [5, 6] have
treated ancestry genetic tests differently than medical or
health-oriented genetic tests. Tests that make health-
related claims or have implications for the prevention,
diagnosis, or treatment of disease have been subject to
greater scrutiny and oversight, as regulators have sought
to ensure that potentially life-changing healthcare deci-
sions are not made on the basis of poor quality informa-
tion or with a lack of appropriate medical knowledge,
advice, and support [7]. Genetic ancestry tests have re-
ceived less attention from legislators, policy makers and
regulatory agencies because they are not marketed expli-
citly for disease diagnosis, treatment, or prevention, and
have thus been seen as more “recreational”, less conse-
quential, and less ethically problematic. This differenti-
ation between ancestry and health genetic testing has
seemed appropriate because the two types of tests have
had such different applications.
However, recent developments demonstrate that the
boundary between ancestry-related and health-related
genetic testing is more porous than previously suggested
[8], and it is being transgressed in a variety of ways.
When genetic testing company 23andMe suspended its
‘health reports’ in 2013, following a warning from the
US Food and Drug Administration (FDA), it continued
to provide customers with ancestry information and
their raw genetic data [9, 10]. With these ancestry testing
data, consumers could still obtain an assessment of their
health risks using independent online ‘interpretation-only’
services for as little as $5 [11]. More explicit links between
genetic ancestry and health are evident in 23andMe’s re-
launched Health + Ancestry Service, which was approved
by the FDA as a ‘medical device’ and provides both ances-
try and health information. This service directly connects
ancestry to health in its ‘wellness’ reports for traits like lac-
tose intolerance and in its ‘carrier status’ reports for med-
ical conditions like cystic fibrosis and sickle cell
anemia, as both link risk estimates to named racial/
ethnic groups. At least one other leading genetic test-
ing company (Ancestry.com) is in discussions with the
FDA about expanding its service to include similar car-
rier status reports [12]. Furthermore, as we show in
this article, even when genetic ancestry tests report
only an individual’s ancestry, consumers can become
aware of possible health risks tied to their genetic
ancestry via media coverage of scientific studies and
online discussion groups.
This blurring of the line between genetic ancestry and
health accentuates the gaps that currently exist in policy
and in the available guidance for consumers because little
attention has been given to the health implications of
genetic ancestry testing. However, as others have noted, it
may become common for consumers to share their ances-
try test results or ancestry-related estimates of disease risk
with their physicians, expecting such information to in-
form their healthcare decisions and improve their quality
of care [13, 14]. It is therefore crucial that we bridge these
gaps to ensure that genetic testing information is used ap-
propriately in health-related decisions and clinical care.
This is especially important because most physicians lack
the expertise needed to interpret and contextualize the re-
sults of genetic tests: only 29% of US clinicians surveyed
rate their knowledge of genetics as excellent, very good, or
good [15], and less than a third of the physicians surveyed
in five European countries were confident or very
confident in their ability to carry out basic medical genetic
tasks [16]. Given these findings, there is a real risk that
consumers or their physicians could make problematic
and potentially irreversible healthcare decisions based on
inaccurate, misleading, or misinterpreted genetic testing
results. Genetic ancestry information has been misinter-
preted or over-interpreted in the past [17–19], and it has
been used in ways that reach far beyond the intended or
anticipated scientific applications — for example, in con-
troversial attempts to use genetic ancestry tests to support
Native American tribal membership claims [20] and to
infer nationality in asylum cases [21].
Thus, it is critical that we recognize and address the
increasingly porous boundary between genetic tests for
ancestry and health because (1) genetic ancestry tests can
provide information that has consequences for health
decision-making, (2) test-takers may have unrealistic
expectations about the scientific and medical certainties
offered by the tests they have purchased, (3) many physi-
cians are not prepared to interpret and apply the genetic
test results that their patients may bring into the clinic,
and (4) better guidance for consumers is needed to ensure
that health-related information from genetic ancestry tests
is interpreted and applied in valid ways. This is especially
important because, as we show in the next section, scien-
tific and biomedical studies have been drawing ever more
connections between ancestry and health, and there is evi-
dence that these connections are beginning to affect con-
sumer interpretations of their genetic ancestry test results.
Mounting evidence of connections between
genetic ancestry and disease risk
Genetic ancestry plays an important role in contemporary
biomedical science. Medical genetic studies, for instance,
Smart et al. BMC Medical Genomics  (2017) 10:3 Page 2 of 9
commonly use ancestry inferences derived from auto-
somal markers (typically single nucleotide polymorphisms
or “ancestry informative markers”) to control for popula-
tion stratification, a practice that underpins the now rou-
tine reporting of population-specific or ancestry-specific
estimates of disease risks and drug response in genetic
epidemiology [13, 22]. Far less attention has been given to
the fact that studies using uniparental genetic markers
have uncovered connections between ancestry and health.
These tests have been a mainstay of the direct-to-consumer
ancestry-testing marketplace, but have been widely con-
sidered to have little biomedical value [13].
Over the last decade, hundreds of biomedical studies
have been published that suggest that certain mito-
chondrial DNA (mtDNA) and Y chromosome variants
(and the haplogroups defined by those variants) are
associated with an increased risk of disease and other
health complications [23]. These variants and hap-
logroups have been linked to a diverse array of common
diseases and medical conditions, including coronary artery
disease, myocardial infarction, ischaemic stroke, heart
transplant complications, Leber hereditary optic neuro-
pathy, advanced age-related macular degeneration,
hearing loss, osteoarthritis, osteoporosis, multiple scler-
osis, Alzheimer’s and Parkinson’s disease, complications
from type 2 diabetes (especially retinopathy, neuro-
pathy, nephropathy, and renal failure), several types of
cancer (breast, thyroid, pancreatic, esophageal, colorec-
tal, prostate, renal, and lung cancer), and the rate of
AIDS progression in HIV patients (an additional table
shows examples of associations discussed in the bio-
medical literature [see Additional file 1]). The exact
causes of these associations are not always clear, but it
is thought that the associated genetic variants alter the
expression of key gene pathways [24] or, in the case of
mtDNA, contribute to the development and progression
of disease by affecting energy metabolism and important
cellular processes, including ATP synthesis, reactive oxy-
gen species (ROS) production, oxygen consumption effi-
ciency, calcium signaling, and apoptosis [25–27].
It is important to note that the quality of studies
reporting associations between mtDNA/Y chromosome
haplogroups and disease susceptibility is quite variable.
Some haplogroup-disease associations are supported by
multiple independent studies with rigorous statistical
designs, but many others are not. The biomedical litera-
ture includes a large number of studies that suffer from
small sample sizes, inappropriate controls for population
stratification, and/or problematic statistics (for example,
P-values that have not been corrected for multiple com-
parisons), so some of the reported haplogroup-disease
associations are almost certainly false positives. Other
researchers have also drawn attention to these problems
[23, 28]. However, regardless of the quality of these
studies, many publications present possible associations
between mtDNA/Y haplogroups and disease risk, and
consumers are becoming aware of these reports as they
garner media attention and enter public discourse.
In 2012, for example, a study published in The Lancet
found that British men belonging to Y chromosome
haplogroup I have a 50% higher age-adjusted risk of
coronary artery disease (CAD) than other British men,
with haplogroup I being the most significant predictor
of CAD after HDL cholesterol and lipid-lowering treat-
ment [24]. This finding was widely reported by the
media in the UK, US, and Australia, under headlines
about heart disease risk being inherited along paternal
lines (Tables 1 and 2). This coverage demonstrated the
potential for raised consumer expectations about the
value of genetic ancestry information to health, and the
future possibilities of acting on that information. One
article, for example, suggested that: “when a screening test
is developed to find those Y chromosome gene clusters
and researchers have a better understanding of how they
act, it may be possible to protect some [unlucky men]
from having heart attacks.” [29] The UK National Health
Service added an extensive discussion of ancestral hap-
logroups and CAD to their patient information website,
NHS Choices, after the study was published — albeit to
argue that this information was not of immediate use for
tackling CAD in the UK because, among other reasons,
“men are unlikely to know their specific haplogroup, so
are unlikely to know whether they may be at increased
risk of CAD” [30]. Ancestry testing consumers dis-
cussed this Lancet study (along with other reports of
haplogroup-associated disease susceptibilities) in online
forums (in threads entitled, for example, “Medical con-
ditions associated with Y-chromosome haplogroups”
and “Do not read if you are a hypochondriac…”), and a
Principal Scientist at 23andMe blogged about the study,
expressing skepticism about the study’s conclusions and
offering an alternative analysis using his company’s data
(Table 3). Thus, by following the circulation of this
study in public domains, we can see variation in how
the study was understood, disagreement over the ro-
bustness of its conclusions, and a lack of clarity about
the significance of genetic ancestry markers like hap-
logroups to health.
While similar observations can be made about studies
of autosomal or genome-wide markers and disease risk,
we have focused here on uniparental genetic markers be-
cause mtDNA and Y chromosome tests are the two
types of genetic ancestry tests that companies, policy-
makers, regulators, and professional scientific associa-
tions have invariably treated as less relevant to health.
However, as we have shown, there is public interest in
the extensive biomedical literature investigating the as-
sociations between mtDNA/Y chromosome haplogroups
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and disease, and some consumers of genetic ancestry
tests are already trying to understand how their an-
cestry is relevant to their health and disease prognosis
in light of these research findings. Other consumers
are also likely to encounter the results of these bio-
medical studies in the popular press, in online for-
ums, in literature from their healthcare provider, or
in well-known medical journals, and they too may
grapple with the possible health implications of their
genetic ancestry test results. Therefore, even when
genetic ancestry tests report only an individual’s an-
cestral lineage or uniparental haplogroup, consumers
can become aware of the possible relationship with
genetic health risks because scientists have linked
haplogroup ancestry to health outcomes.
Conclusions
Like the repurposing of genome-wide ancestry test data
to assess health risks, and like the use of autosomal
genetic markers in genetic epidemiology to identify
population-specific disease risks and drug response, the
reported associations between uniparentally-inherited
haplogroups and various diseases represent another
blurring of the line between genetic information on
health and ancestry. Developments in scientific know-
ledge and commercial practice appear to be outpacing
the current oversight and governance regimes that
largely treat genetic tests for ancestry and health as sep-
arate and distinct.
We therefore suggest that it is time for the various
stakeholders in genetic ancestry testing to reconsider
what they communicate about the health implications of
ancestry information, both to the public and to each
other. This will require considering some difficult ques-
tions. For example, can and should consumer genetic
testing companies take responsibility for the ways in
which test-takers connect ancestry test results with other
publicly available information? Can and should genetic
testing companies, alongside scientific associations and
consumer advocates, provide guidance to consumers
about the accuracy and reliability of the various postu-
lated associations between haplogroups (or other genetic
markers) and health risks? How can those who commu-
nicate about the relevant science (scientific researchers,
journal editors, science journalists, genetic testing
companies, consumer advocates, policy advisors, etc.)
achieve maximum clarity regarding the potential health
implications of genetic ancestry (or the lack of them),
and make effective use of the published critiques of the
putative links between uniparental haplogroups and
health risks [23, 28]? Should there be any changes to
policies governing the regulation or oversight of con-
sumer genetic testing, or additions to guidelines being
developed by professional associations like the American
Society of Human Genetics (ASHG)?
To help address the issues raised here, we make five
recommendations for stakeholders in consumer genetic
testing to consider:
(1) The ASHG or another respected professional
genetics society should organize a roundtable
to bring the various stakeholders together to
produce authoritative guidance that will inform
and benefit consumers, and help create a set of
standards for the industry to follow. This guidance
should make clear what we can and cannot
know from genetic ancestry testing, and provide
guidance regarding the accuracy and reliability of
associations between genetic markers and health
risks. Industry representatives, consumer advocates,
policy and legal advisors, biomedical researchers,
social scientists, and regulators should all be
involved in drafting this guidance.
(2) Consumer advocates, scientific organizations,
companies, science journalists, and government
agencies should play a role in making this
information available to consumers.
(3)Genetic ancestry testing companies should
report only associations between genetic
markers and diseases/medical conditions that
have been scientifically validated. They should
also provide information about the limitations of
their tests (as 23andMe now does as part of their
‘carrier status’ and ‘wellness’ reports; [31]) and
include information about how to interpret the
connections between ancestry and health among
their FAQs.
(4)Medical schools and continuing medical education
(CME) programs should discuss the potential health
implications of genetic ancestry information so that
physicians can help their patients to interpret and
contextualize their genetic testing results.
(5) Policy-makers and government agencies may
wish to reconsider current oversight regimes for
direct-to-consumer genetic testing in light of the
increasingly porous boundaries between tests for
health and ancestry.
Our recommendations are aimed at encouraging
novel and timely interventions into ongoing debates
about direct-to-consumer genetic tests, especially
since the US FDA, European Commission, ASHG, and
high-profile ancestry testing companies are all consid-
ering scientific, ethical, and regulatory issues regarding
health-related genetic testing. Now is the time to start
bridging the gap in our current approaches to health
and ancestry genetic testing.
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Additional file
Additional file 1: Examples of associations between mitochondrial DNA
(mtDNA) or Y chromosome variants and diseases/medical traits discussed
in the biomedical literature. Description of data: an extensive list of published
associations between mitochondrial DNA (mtDNA) or Y chromosome variants
and diseases/medical traits. Organised by disease/medical traits, and including:
mtDNA or Y Chromosome Variant; Proposed Association (or Lack of
Association); Study Location; and Reference. (DOCX 58 kb)
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Additional File 1. Examples of associations between mitochondrial DNA (mtDNA) or Y chromosome variants and diseases/medical traits discussed in the 
biomedical literature. 
 
Note: Published associations were included regardless of the quality of statistical analysis or the robustness of the reported association. Some of the associations 
listed here are likely false positives. This is not a comprehensive listing of all relevant studies and does not include all reported associations. 
 
 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Longevity    
mtDNA haplogroup D4 longevity China X. Y. Cai, et al., Association of mitochondrial DNA haplogroups with exceptional 
longevity in a Chinese population. PloS ONE 4, e6423 (2009), 
10.1371/journal.pone.0006423. 
mtDNA haplogroups M9, N9, 
B4a 
reduced longevity China X. Y. Cai, et al., Association of mitochondrial DNA haplogroups with exceptional 
longevity in a Chinese population. PloS ONE 4, e6423 (2009), 
10.1371/journal.pone.0006423. 
mtDNA 150T longevity Costa Rica L. Castri et al., Mitochondrial polymorphisms associated with differential longevity do 
not impact lifetime-reproductive success. Am J Hum Biol 23, 225-227 (2011). 
mtDNA 5178A in haplogroup 
D 
reduced longevity Costa Rica L. Castri et al., Mitochondrial polymorphisms associated with differential longevity do 
not impact lifetime-reproductive success. Am J Hum Biol 23, 225-227 (2011). 
mtDNA haplogroups D4a, D5, 
D4b2b 
longevity Japan, Korea Y. Nishigaki, N. Fuku, M. Tanaka, Mitochondrial haplogroups associated with lifestyle-
related diseases and longevity in the Japanese population. Geriatr Gerontol Int 10 
Suppl 1, S221-235 (2010). 
mtDNA haplogroup F longevity China J. Feng et al., Association of mtDNA haplogroup F with healthy longevity in the female 
Chuang population, China. Exp Gerontol 46, 987-993 (2011). 
mtDNA 150T  no association with 
longevity 
China H. Pan et al., Absence of association between mitochondrial DNA C150T 
polymorphism and longevity in a Han Chinese population. Exp Gerontol 46, 511-515 
(2011). 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Longevity (cont.)    
mtDNA haplogroups no association with 
longevity 
Spain T. Pinos et al., Are mitochondrial haplogroups associated with extreme longevity? A 
study on a Spanish cohort. Age (Dordr) 34, 227-233 (2012). 
mtDNA haplogroup X successful aging USA M. D. Courtenay et al., Mitochondrial haplogroup X is associated with successful aging 
in the Amish. Hum Genet 131, 201-208 (2012). 
mtDNA haplogroup J less successful aging USA M. D. Courtenay et al., Mitochondrial haplogroup X is associated with successful aging 
in the Amish. Hum Genet 131, 201-208 (2012). 
mtDNA 150T, 73G longevity Turkey O. Guney et al., Mitochondrial DNA polymorphisms associated with longevity in the 
Turkish population. Mitochondrion 17, 7-13 (2014). 
mtDNA haplogroup D4b2 and 
1382C 
longevity Japan N. Fuku et al., The mitochondrial-derived peptide MOTS-c: a player in exceptional 
longevity? Aging Cell 14, 921-923 (2015). 
mtDNA haplogroups no association with 
longevity 
China Y.-H. He et al., Mitochondrial DNA plays an equal role in influencing female and male 
longevity in centenarians. Exp Geront 83, 94-96 (2016). 
mtDNA haplogroup M9 reduced longevity China L. Li et al., Mitochondrial genomes and exceptional longevity in a Chinese population: 
the Rugao longevity study. Age 37, 14 (2015). 
mtDNA haplogroups A4h, 
R11a1a1a 
longevity China L. Li et al., Mitochondrial genomes and exceptional longevity in a Chinese population: 
the Rugao longevity study. Age 37, 14 (2015). 
mtDNA haplogroup C reduced longevity Costa Rica L. Castri et al., A mitochondrial haplogroup is associated with decreased longevity in a 
historic New World population. Hum Biol 86, 251-259 (2014). 
Cancer    
mtDNA 239C, 263G, 16207T, 
haplogroup I 
breast cancer Poland A. M. Czarnecka et al, Mitochondrial genotype and breast cancer predisposition. Oncol 
Rep 24, 1521-1534 (2010). 
mtDNA 73G, 150T, 16183C, 
16189C, 16223T, 16362C  
reduced risk of breast 
cancer 
Poland A. M. Czarnecka et al, Mitochondrial genotype and breast cancer predisposition. Oncol 
Rep 24, 1521-1534 (2010). 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Cancer (cont.)    
linked mtDNA 16183C, 
16189C, 16192T, 16270T, 
195T  
malignant melanoma Middle Europe S. Ebner et al., Mitochondrial haplogroups, control region polymorphisms and 
malignant melanoma: a study in middle European Caucasians. PLoS One 6, e27192 
(2011), 10.1371/journal.pone.0027192. 
mtDNA haplogroups M, D5 breast cancer China H. Fang et al., Cancer type-specific modulation of mitochondrial haplogroups in breast, 
colorectal and thyroid cancer. BMC Cancer 10, 421 (2010). 
mtDNA haplogroup D4a thyroid cancer China H. Fang et al., Cancer type-specific modulation of mitochondrial haplogroups in breast, 
colorectal and thyroid cancer. BMC Cancer 10, 421 (2010). 
mtDNA haplogroup Uk vulvar squamous cell 
carcinoma 
Poland A. Klemba et al., Mitochondrial genotype in vulvar carcinoma - cuckoo in the nest. J 
Biomed Sci 17, 73 (2010). 
mtDNA haplogroup H reduced risk of vulvar 
squamous cell carcinoma 
Poland A. Klemba et al., Mitochondrial genotype in vulvar carcinoma - cuckoo in the nest. J 
Biomed Sci 17, 73 (2010). 
various rare mtDNA variants pancreatic cancer USA E. T. Lam et al., Mitochondrial DNA sequence variation and risk of pancreatic cancer. 
Cancer Res 72, 686-695 (2012). 
mtDNA haplogroup D 
(especially D4a, D5) 
esophageal cancer China X. Y. Li et al., Association of mitochondrial haplogroup D and risk of esophageal 
cancer in Taihang Mountain and Chaoshan areas in China. Mitochondrion 11, 27-32 
(2011). 
mtDNA haplogroup U prostate cancer USA L. M. Booker et al, North American white mitochondrial haplogroups in prostate and 
renal cancer. J Urol 175, 468-472 (2006). 
mtDNA haplogroup U no association with 
prostate cancer 
Middle Europe E. E. Mueller et al., Mitochondrial haplogroups and control region polymorphisms are 
not associated with prostate cancer in Middle European Caucasians. PLoS One 4, e6370 
(2009), 10.1371/journal.pone.0006370. 
mtDNA haplogroup M breast cancer China L. Shen et al., Evaluating mitochondrial DNA in cancer occurrence and development. 
Ann N Y Acad Sci 1201, 26-33 (2010). 
 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Cancer (cont.)    
mtDNA haplogroup M5 breast cancer India N. R. Tipirisetti et al., Mitochondrial genome variations in advanced stage breast 
cancer: a case-control study. Mitochondrion 13, 372-378 (2013). 
mtDNA 752A, 1440A, 4770A  colorectal cancer Scotland E. Theodoratou et al., Association between common mtDNA variants and all-cause or 
colorectal cancer mortality. Carcinogenesis 31, 296-301 (2010). 
mtDNA haplogroups D, F reduced risk of lung 
cancer 
China S. Zheng et al., Association of mitochondrial DNA variations with lung cancer risk in a 
Han Chinese population from southwestern China. PLoS One 7, e31322 (2012), 
10.1371/journal.pone.0031322. 
mtDNA haplogroups G, M7 lung cancer China S. Zheng et al., Association of mitochondrial DNA variations with lung cancer risk in a 
Han Chinese population from southwestern China. PLoS One 7, e31322 (2012), 
10.1371/journal.pone.0031322. 
mtDNA haplogroup JT myelodysplastic 
syndromes 
USA J. N. Poynter et al., Association between mitochondrial DNA haplogroup and 
myelodysplastic syndromes. Genes Chromosomes Cancer 55, 9 (2016), 
10.1002/gcc.22370. 
mtDNA haplogroups no association with 
prostate cancer 
Colombia D. Cano et al., Mitochondrial DNA haplogroups and susceptibility to prostate cancer in 
a colombian population. ISRN Oncol. 530675 (2014), 10.1155/2014/530675. 
mtDNA no association with 
prostate cancer 
USA E. E. Giorgi et al., No Association between the Mitochondrial Genome and Prostate 
Cancer Risk: The Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev. 25, 6 (2016), 
10.1158/1055-9965. 
mtDNA haplogroup T colorectal cancer USA Y. Li et al., Association of Genes, Pathways, and Haplogroups of the Mitochondrial 
Genome with the Risk of Colorectal Cancer: The Multiethnic Cohort. PLoS One 10, 
e0136796 (2015), 10.1371/journal.pone.0136796. 
mtDNA haplogroup H breast cancer Uruguay C. Bonilla et al, Breast cancer risk and genetic ancestry: a case-control study in 
Uruguay. BMC Womens Health. 15, 11 (2015) 10.1186/s12905-015-0171-8. 
 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Cancer (cont.)    
mtDNA haplogroups R9, F1 nasopharyngeal carcinoma China S. P. Hu, J. P. Du, D. R. Li, Y. G. Yao, Mitochondrial DNA haplogroup confers genetic 
susceptibility to nasopharyngeal carcinoma in Chaoshanese from Guangdong, China. 
PLoS One 9, e87795 (2014), 10.1371/journal.pone.0087795. 
Coronary Conditions    
mtDNA haplogroups N9b, M7c reduced risk of myocardial 
infarction 
Japan, Korea Y. Nishigaki, N. Fuku, M. Tanaka, Mitochondrial haplogroups associated with lifestyle-
related diseases and longevity in the Japanese population. Geriatr Gerontol Int 10 
Suppl 1, S221-235 (2010). 
mtDNA haplogroup G1 myocardial infarction Japan, Korea Y. Nishigaki, N. Fuku, M. Tanaka, Mitochondrial haplogroups associated with lifestyle-
related diseases and longevity in the Japanese population. Geriatr Gerontol Int 10 
Suppl 1, S221-235 (2010). 
mtDNA 16189C coronary artery disease & 
myocardial infarction 
Saudi Arabia K. K. Abu-Amero et a.l, The mitochondrial DNA variant 16189T>C Is associated with 
coronary artery disease and myocardial infarction in Saudi Arabs. Genet Test Mol 
Bioma 14, 43-47 (2010). 
mtDNA haplogroup H reduced risk of left 
ventricular hypertrophy 
Russia S. V. Buikin, M. V. Golubenko, V. P. Puzyrev, Genes for mitochondria in arterial 
hypertension and left ventricular hypertrophy. Mol Biol 44, 23-27 (2010).  
mtDNA haplogroup T left ventricular 
hypertrophy 
Russia S. V. Buikin, M. V. Golubenko, V. P. Puzyrev, Genes for mitochondria in arterial 
hypertension and left ventricular hypertrophy. Mol Biol 44, 23-27 (2010).  
Y chromosome haplogroup I coronary artery disease UK F. J. Charchar et al., Inheritance of coronary artery disease in men: an analysis of the 
role of the Y chromosome. Lancet 379, 915-922 (2012).  
mtDNA haplogroup K reduced risk of transient 
ischaemic attack, & 
ischaemic stroke 
UK P. F. Chinnery et al., Mitochondrial DNA haplogroups and risk of transient ischaemic 
attack and ischaemic stroke: a genetic association study. Lancet Neurol 9, 498-503 
(2010). 
 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Coronary Conditions (cont.)    
mtDNA haplogroup H end-stage heart failure Europe M. E. Gallardo et al., Mitochondrial haplogroups associated with end-stage heart failure 
and coronary allograft vasculopathy in heart transplant patients. Eur Heart J 33, 346-
353 (2012).  
mtDNA haplogroup Uk cardiac allograft 
vasculopathy 
Europe M. E. Gallardo et al., Mitochondrial haplogroups associated with end-stage heart failure 
and coronary allograft vasculopathy in heart transplant patients. Eur Heart J 33, 346-
353 (2012).  
mtDNA haplogroup W coronary artery disease Lebanon M. Haber et al., mtDNA lineages reveal coronary artery disease-associated structures in 
the Lebanese population. Ann Hum Genet 76, 1-8 (2012). 
mtDNA haplogroup T coronary artery disease Austria B. Kofler et al., Mitochondrial DNA haplogroup T is associated with coronary artery 
disease and diabetic retinopathy: a case control study. BMC Med Genet 10, 35 (2009), 
10.1186/1471-2350-10-35. 
mtDNA 16189C coronary artery disease Austria E. E. Mueller et al., The mitochondrial T16189C polymorphism is associated with 
coronary artery disease in Middle European populations. PLoS One 6, e16455 (2011), 
10.1371/journal.pone.0016455. 
mtDNA haplogroup H early-onset myocardial 
infarction 
Spain M. Palacin et al., Mitochondrial DNA and TFAM gene variation in early-onset 
myocardial infarction: evidence for an association to haplogroup H. Mitochondrion 11, 
176-181 (2011). 
mtDNA haplogroups A, M7a coronary atherosclerosis Japan M. Sawabe et al., Mitochondrial haplogroups A and M7a confer a genetic risk for 
coronary atherosclerosis in the Japanese elderly: an autopsy study of 1,536 patients. J 
Atheroscler Thromb 18, 166-175 (2011). 
Y chromosome haplogroup K atherosclerotic plaque 
occurrence 
Cyprus K. Voskarides, D. Hadjipanagi, L. Papazachariou, M. Griffin, A. G. Panayiotou, 
Evidence for contribution of the Y chromosome in atherosclerotic plaque occurrence in 
men. Genet Test Mol Biomarkers 18, 552-556 (2014). 
 
 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Coronary Conditions (cont.)    
Y chromosome haplogroup 
YAP 
reduced risk of 
atherosclerotic plaque 
Cyprus K. Voskarides, D. Hadjipanagi, L. Papazachariou, M. Griffin, A. G. Panayiotou, 
Evidence for contribution of the Y chromosome in atherosclerotic plaque occurrence in 
men. Genet Test Mol Biomarkers 18, 552-556 (2014). 
Y chromosome haplogroups no association with 
cardiovascular risk 
Poland G. Kostrzewa, G. Broda, M. Konarzewska, P. Krajewki, R. Płoski. Genetic 
polymorphism of human Y chromosome and risk factors for cardiovascular diseases: a 
study in WOBASZ cohort. PLoS ONE 8, e68155 (2013), 
doi:10.1371/journal.pone.0068155. 
mtDNA haplogroup H hypertrophic 
cardiomyopathy 
Denmark C. M. Hagen et al., Mitochondrial haplogroups modify the risk of developing 
hypertrophic cardiomyopathy in a Danish population. PLoS One 8, e71904 (2013), 
10.1371/journal.pone.0071904. 
Y chromosome haplogroups no association with 
recurrent venous 
thrombosis 
Holland H. G. de Haan et al., Male-specific risk of first and recurrent venous thrombosis: a 
phylogenetic analysis of the Y chromosome. J Thromb Haemost. (2016), doi: 
10.1111/jth.13437. 
mtDNA haplogroup D4b reduced risk of ischemic 
stroke 
China D. Yang et al., Mitochondrial DNA haplogroup D4b is a protective factor for ischemic 
stroke in Chinese Han population. Mol Genet Genomics. 289, 6, 1241-6 (2014). 
mtDNA haplogroup N9 facilitates neurological 
recovery after ischemic 
stroke 
China B. Cai et al., Mitochondrial DNA haplogroups and short-term neurological outcomes of 
ischemic stroke. Sci Rep 20, 5, 9864 (2015), 10.1038/srep09864. 
mtDNA haplogroup H subclinical carotid 
atherosclerosis 
Russia A. Zhelankin et al., 1A.06: Mitochondrial DNA haplogroup H is associated with 
subclinical carotid atherosclerosis in Russian population. J Hypertens 33 suppl 1:e2 
(2015), 10.1097/01.hjh.0000467356.04711.5 
mtDNA haplogroups J, Uk reduced risk of 
hypertrophic 
cardiomyopathy 
Denmark C. M. Hagen et al., Mitochondrial haplogroups modify the risk of developing 
hypertrophic cardiomyopathy in a Danish population. PLoS One 8, e71904 (2013), 
10.1371/journal.pone.0071904. 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Type 2 Diabetes    
mtDNA haplogroups F, D4b type 2 diabetes Japan, Korea Y. Nishigaki, N. Fuku, M. Tanaka, Mitochondrial haplogroups associated with lifestyle-
related diseases and longevity in the Japanese population. Geriatr Gerontol Int 10 
Suppl 1, S221-235 (2010). 
mtDNA haplogroups H, H3, 
U3, V 
complications from 
diabetes 
Italy A. Achilli et al., Mitochondrial DNA backgrounds might modulate diabetes 
complications rather than T2DM as a whole. PLoS One 6, e21029 (2011), 
10.1371/journal.pone.0021029. 
mtDNA haplogroup N9a reduced risk of type 2 
diabetes 
Japan, Korea Y. Nishigaki, N. Fuku, M. Tanaka, Mitochondrial haplogroups associated with lifestyle-
related diseases and longevity in the Japanese population. Geriatr Gerontol Int 10 
Suppl 1, S221-235 (2010). 
mtDNA haplogroup J1 type 2 diabetes Europe,            
North Africa 
J. Feder et al., Parental diabetes status reveals association of mitochondrial DNA 
haplogroup J1 with type 2 diabetes. BMC Med Genet 10, 60 (2009), 10.1186/1471-
2350-10-60. 
mtDNA 16189C no association with type 2 
diabetes 
China L. Zhong et al., Reappraising the relationship between mitochondrial DNA variant 
m.16189t > c and type 2 diabetes mellitus in East Asian populations. Curr Mol Med 14, 
1273-1278 (2014). 
mtDNA 16390A type 2 diabetes Tunisia S. Hsousa, et al., Association study of mitochondrial DNA polymorphisms with type 2 
diabetes in Tunisian population. Mitochondr DNA 26, 367-372 (2015). 
mtDNA haplogroups M8a, N9a type 2 diabetes China Q. Niu et al., Effects of mitochondrial haplogroup N9a on type 2 diabetes mellitus and 
its associated complications. Exp Ther Med 10, 1918-1924 (2015). 
mtDNA 3243G, 16189C type 2 diabetes Asia S. H. Kwak, K. S. Park, Role of mitochondrial DNA variation in the pathogenesis of 
diabetes mellitus. Front Biosci (Landmark Ed.) 21, 1151-1167 (2016). 
mtDNA haplogroups and 
mutations 
no association with type 2 
diabetes 
Denmark S. Li et al., Variation and association to diabetes in 2000 full mtDNA sequences mined 
from an exome study in a Danish population. Eur J Hum Genet 22, 1040-1045 (2014).  
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Hearing Loss    
mtDNA haplogroup L1 noise-induced hearing loss Brazil R. S. Abreu-Silva et al., The search of a genetic basis for noise-induced hearing loss 
(NIHL). Ann Hum Biol 38, 210-218 (2011). 
mtDNA 1555G  aminoglycoside-induced, 
non-syndromic hearing 
loss 
China Y. Bai et al., A six-generation Chinese family in haplogroup B4C1C exhibits high 
penetrance of 1555A > G-induced hearing Loss. BMC Med Genet 11, 129 (2010), 
10.1186/1471-2350-11-129. 
mtDNA 1555G non-syndromic 
sensorineural hearing loss 
Morocco H. Nahili et al., Prevalence of the mitochondrial A 1555G mutation in Moroccan 
patients with non-syndromic hearing loss. Int J Pediatr Otorhinolaryngol 74, 1071-1074 
(2010). 
mtDNA 1555G aminoglycoside-induced, 
non-syndromic hearing 
loss 
China J. Lu et al., Mitochondrial haplotypes may modulate the phenotypic manifestation of the 
deafness-associated 12S rRNA 1555A>G mutation. Mitochondrion 10, 69-81 (2010). 
mtDNA 1555G, haplogroup B higher risk, penetrance, & 
expressivity of hearing 
loss 
China J. Lu et al., Mitochondrial haplotypes may modulate the phenotypic manifestation of the 
deafness-associated 12S rRNA 1555A>G mutation. Mitochondrion 10, 69-81 (2010). 
mtDNA 1555G, 961G non-syndromic 
sensorineural hearing loss 
Italy V. Guaran et al., Association between idiopathic hearing loss and mitochondrial DNA 
mutations: a study on 169 hearing-impaired subjects. Int J Mol Med 32, 785-794 (2013). 
mtDNA 1555G, 3243G, 
3595G, 6204G 
non-syndromic hearing 
loss 
Japan T. Yano et al., Frequency of mitochondrial mutations in non-syndromic hearing loss as 
well as possibly responsible variants found by whole mitochondrial genome screening. J 
Hum Genet 59, 100-106 (2014). 
mtDNA 1222G non-syndromic 
sensorineural hearing loss 
China Q. Wei et al., Genetic mutations of GJB2 and mitochondrial 12S rRNA in 
nonsyndromic hearing loss in Jiangsu Province of China. J Transl Med 11, 163 (2013). 
mtDNA 1555G, haplogroup B aminoglycoside-induced, 
non-syndromic hearing 
loss 
China Z. Ying et al., Mitochondrial haplogroup B increases the risk for hearing loss among the 
Eastern Asian pedigrees carrying 12S rRNA 1555A>G mutation. Protein Cell 6, 844-
848 (2015). 
 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Hearing Loss (cont.)    
mtDNA haplogroups D4a, 
M22, H2 
aminoglycoside-induced, 
non-syndromic hearing 
loss 
China X. Tang et al., Mitochondrial tRNA(Ser(UCN)) variants in 2651 Han Chinese subjects 
with hearing loss. Mitochondrion 23, 17-24 (2015). 
mtDNA haplogroups and 
mutations 
no association with age-
related hearing impairment 
Belgium S. Bonneaux et al., Inherited mitochondrial variants are not a major cause of age-related 
hearing impairment in the European population. Mitochondrion 11, 729-734 (2011). 
mtDNA 7505C non-syndromic hearing 
loss 
China X. Tang et al., Maternally inherited hearing loss is associated with the novel 
mitochondrial tRNA Ser(UCN) 7505T>C mutation in a Han Chinese family. Mol Genet 
Metab 100, 57-64 (2010). 
Hypertension    
mtDNA 4291C hypertension, hypercho-
lesterolemia, 
hypomagnesemia 
USA F. H. Wilson et al., A cluster of metabolic defects caused by mutation in a 
mitochondrial tRNA. Science 306, 1190-1194 (2004). 
mtDNA 4401G hypertension China R. Li et al., Failures in mitochondrial tRNAMet and tRNAGln metabolism caused by 
the novel 4401A>G mutation are involved in essential hypertension in a Han Chinese 
Family. Hypertension 54, 329-337 (2009). 
mtDNA 4435G hypertension China Z. Lu et al., The tRNAMet 4435A>G mutation in the mitochondrial haplogroup G2a1 is 
responsible for maternally inherited hypertension in a Chinese pedigree. Eur J Hum 
Genet 19, 1181-1186 (2011). 
mtDNA 4295G hypertension China Z. Li, Y. Liu, L. Yang, S. Wang, M. X. Guan, Maternally inherited hypertension is 
associated with the mitochondrial tRNAIle A4295G mutation in a Chinese family. 
Biochem Biophys Res Commun 367, 906-911 (2008). 
mtDNA haplogroup H not associated with 
hypertension  
Russia A. Zhelankin et al., 1A.06: Mitochondrial DNA haplogroup H is associated with 
subclinical carotid atherosclerosis in Russian population. J Hypertens 33 suppl 
1:e2 (2015), 10.1097/01.hjh.0000467356.04711.5 
B.  
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Hypertension (cont.)    
mtDNA haplogroups M, HV, 
JT, UK 
pulmonary arterial 
hypertension 
USA S. Farha et al., Mitochondrial Haplogroups and Risk of Pulmonary Arterial 
Hypertension. PLoS One 11, e0156042 (2016). 
mtDNA haplogroup L reduced risk of pulmonary 
arterial hypertension 
USA S. Farha et al., Mitochondrial Haplogroups and Risk of Pulmonary Arterial 
Hypertension. PLoS One 11, e0156042 (2016). 
mtDNA 4263G hypertension China S. Wang et al., Maternally inherited essential hypertension is 
associated with the novel 4263A4G mutation in the mitochondrial tRNAIle gene in a 
large Han Chinese family. Circ Res 108, 862-870 (2011). 
Infertility    
Y chromosome haplogroup K male infertility Latvia A. Puzuka et al., Y chromosome—a tool in infertility studies of Latvian population. 
Russian Journal of Genetics 47, 347-353 (2011). 
Y chromosome haplogroups F, 
K, P, N1 
male infertility China J. Ran et al., Association study between Y-chromosome haplogroups and susceptibility 
to spermatogenic impairment in Han People from southwest China. Genet Mol Res 12, 
59-66 (2013). 
Bone Disease    
mtDNA haplogroup U increased severity of knee 
osteoarthritis 
Spain I. Rego-Perez, M. Fernandez-Moreno, C. Fernandez-Lopez, J. Arenas, F. Blanco, 
Mitochondrial DNA haplogroups: role in the prevalence and severity of knee 
osteoarthritis. Arthritis Rheum 58, 2387-2396 (2008). 
mtDNA haplogroup J reduced risk of knee 
osteoarthritis 
Spain I. Rego-Perez, M. Fernandez-Moreno, C. Fernandez-Lopez, J. Arenas, F. Blanco, 
Mitochondrial DNA haplogroups: role in the prevalence and severity of knee 
osteoarthritis. Arthritis Rheum 58, 2387-2396 (2008). 
mtDNA haplogroup J reduced risk of hip 
osteoarthritis 
Spain I. Rego, et al., Role of european mitochondrial DNA haplogroups in the prevalence of 
hip osteoarthritis in Galicia, Northern Spain. Ann Rheum Dis 69, 210-213 (2010). 
mtDNA haplogroup X lower hip bone mineral 
density (osteoporosis) 
USA Y. Guo et al., Mitochondria-wide association study of common variants in osteoporosis. 
Ann Hum Genet 75, 569-574 (2011). 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Bone Disease (cont.)   
mtDNA 4823C lower hip bone mineral 
density (osteoporosis) 
USA Y. Guo et al., Mitochondria-wide association study of common variants in osteoporosis. 
Ann Hum Genet 75, 569-574 (2011). 
mtDNA haplogroup G knee osteoarthritis China H. Fang et al., Role of mtDNA haplogroups in the prevalence of knee osteoarthritis in a 
southern Chinese population. Int J Mol Sci 15, 2646-2659 (2014). 
mtDNA haplogroups B, B4 reduced risk of knee 
osteoarthritis 
China H. Fang et al., Role of mtDNA haplogroups in the prevalence of knee osteoarthritis in a 
southern Chinese population. Int J Mol Sci 15, 2646-2659 (2014). 
mtDNA haplogroups J, T reduced risk of 
osteoarthritis 
UK, Spain A. Soto-Hermida et al., mtDNA haplogroups and osteoarthritis in different geographic 
populations. Mitochondrion 15, 18-23 (2014). 
mtDNA haplogroups J, TJ osteoarthritis Spain J. M. Shen, et al., Role of mtDNA haplogroups in the prevalence of osteoarthritis in 
different geographic populations: a meta-analysis. PLoS One 9, e108896 (2014). 
doi:10.1371/journal.pone.0108896 
mtDNA haplogroup TJ slower osteoarthritis 
progression 
Spain A. Soto-Hermida et al., Mitochondrial DNA haplogroups modulate the radiographic 
progression of Spanish patients with osteoarthritis. Rheumatol Int 35, 337-344 (2015). 
mtDNA haplogroup H more joint surgery for 
osteoarthritis 
Spain A. Soto-Hermida et al., Mitochondrial DNA haplogroups modulate the radiographic 
progression of Spanish patients with osteoarthritis. Rheumatol Int 35, 337-344 (2015). 
mtDNA haplogroups no association with 
osteoarthritis 
UK G. Hudson et al., No evidence of an association between mitochondrial DNA variants 
and osteoarthritis in 7393 cases and 5122 controls. Ann Rheum Dis 72, 136-139 (2013). 
AIDS/HIV Antiviral Therapy Complications   
mtDNA haplogroups U5a, J accelerated AIDS 
progression 
USA S. L. Hendrickson et al., Mitochondrial DNA haplogroups influence AIDS progression. 
AIDS 22, 2429-2439 (2008). 
mtDNA haplogroups I, W, X, 
H3 
delayed onset of AIDS USA S. L. Hendrickson et al., Mitochondrial DNA haplogroups influence AIDS progression. 
AIDS 22, 2429-2439 (2008). 
 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
AIDS/HIV Antiviral Therapy Complications (cont.)  
mtDNA haplogroup Uk reduced risk of AIDS USA S. L. Hendrickson et al., Mitochondrial DNA haplogroups influence AIDS progression. 
AIDS 22, 2429-2439 (2008). 
mtDNA haplogroup L1c peripheral neuropathy 
during HIV antiretroviral 
therapy 
USA J. A. Canter et al., African mitochondrial DNA subhaplogroups and peripheral 
neuropathy during antiretroviral therapy. J Infect Dis 201, 1703-1707 (2010). 
mtDNA haplogroup L2 slower CD4 T-cell 
recovery during HIV 
antiretroviral therapy 
USA B. J. Grady et al., Mitochondrial genomics and CD4 T-cell count recovery after 
antiretroviral therapy initiation in AIDS clinical trials group study 384. J Acquir 
Immune Defic Syndr 58, 363-370 (2011). 
mtDNA haplogroup I lipoatrophy during HIV 
antiretroviral therapy 
USA T. Hulgan et al., European mitochondrial DNA haplogroups and metabolic changes 
during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25, 37-
47 (2011). 
mtDNA haplogroup J reduced risk of 
neuroretinal disorder 
during HIV antiretroviral 
therapy 
USA S. L. Hendrickson et al., Genetic variants in nuclear-encoded mitochondrial genes 
influence AIDS progression. PLoS One 5, e12862 (2010), 
10.1371/journal.pone.0012862. 
mtDNA haplogroup L2 slower CD4 T-cell 
recovery during HIV 
antiretroviral therapy 
USA B. Aissani et al., Mitochondrial DNA variation and virologic and immunological HIV 
outcomes in African Americans. AIDS 28, 1871-1878 (2014). 
mtDNA haplogroups J, T slower CD4 T-cell 
recovery during HIV 
antiretroviral therapy 
Spain M. Guzman-Fulgencio et al., European mitochondrial haplogroups are associated with 
CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy. J 
Antimicrob Chemother 68, 2349-2357 (2013). 
European mtDNA haplogroups not associated with 
hepatitis C virus treatment 
response 
Spain M. Guzmán-Fulgencio et al., European mitochondrial haplogroups are not associated 
with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients. HIV 
Med 15, 425-430 (2014). 
mtDNA haplogroup A susceptibility to AIDS China H. W. Wang, et al., Mitochondrial DNA Haplogroup A may confer a genetic 
susceptibility to AIDS group from Southwest China.Mitochondrial DNA A DNA Mapp 
Seq Anal 27, 2221-2224 (2016). 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
AIDS/HIV Antiviral Therapy Complications (cont.)  
mtDNA haplogroup B less neurocognitive 
impairment during HIV 
antiretroviral therapy 
USA T. Hulgan et al., Mitochondrial DNA Haplogroups and Neurocognitive Impairment 
During HIV Infection. Clin Infect Dis 61, 1476-1484 (2015). 
mtDNA haplogroup H faster CD4 T-cell recovery 
during HIV antiretroviral 
therapy 
Spain M. Guzman-Fulgencio et al., European mitochondrial haplogroups are associated with 
CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy. J 
Antimicrob Chemother 68, 2349-2357 (2013). 
Neurodegenerative Conditions/Treatment Response  
mtDNA haplogroup H (7028C) earlier onset of 
Huntington's disease 
Germany L. Arning et al., Mitochondrial haplogroup H correlates with ATP levels and age at 
onset in Huntington disease. J Mol Med (Berl) 88, 431-436 (2010). 
mtDNA haplogroup H (7028C) late onset Alzheimer's 
disease 
Spain E. Coto et al., Late-onset Alzheimer's disease is associated with mitochondrial DNA 
7028C/haplogroup H and D310 poly-C tract heteroplasmy. Neurogenetics 12, 345-346 
(2011). 
mtDNA haplogroups J1c, J2, 
U4, U5a1, K 
reduced risk of Parkinson's 
disease 
Poland K. Gaweda-Walerych et al., Mitochondrial transcription factor A variants and the risk 
of Parkinson's disease. Neurosci Lett 469, 24-29 (2010). 
mtDNA haplogroup H Alzheimer's and 
Parkinson's diseases 
Spain A. Gomez-Duran et al., Unmasking the causes of multifactorial disorders: OXPHOS 
differences between mitochondrial haplogroups. Hum Mol Genet 19, 3343-3353 (2010). 
mtDNA haplogroup Uk reduced risk of 
Alzheimer's and 
Parkinson's disease 
Spain A. Gomez-Duran et al., Unmasking the causes of multifactorial disorders: OXPHOS 
differences between mitochondrial haplogroups. Hum Mol Genet 19, 3343-3353 (2010). 
mtDNA haplogroup Uk Alzheimer's disease USA, Canada A. Lakatos et al., Association between mitochondrial DNA variations and Alzheimer's 
disease in the ADNI cohort. Neurobiol Aging 31, 1355-1363 (2010). 
 
 
 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Neurodegenerative Conditions/Treatment Response (cont.)  
mtDNA haplogroups no association with 
Alzheimer's disease 
N.A. M. Mancuso, V. Calsolaro, D. Orsucci, G. Siciliano, L. Murri, Is there a primary role of 
the mitochondrial genome in Alzheimer's disease? J Bioenerg Biomembr 41, 411-416 
(2009). 
mtDNA haplogroup E1 Parkinson's disease Guam D. M. Reiff et al., Inherited and somatic mitochondrial DNA mutations in Guam 
amyotrophic lateral sclerosis and parkinsonism-dementia. Neurol Sci 32, 883-892 
(2011). 
mtDNA haplogroup E2 reduced risk of Parkinson's 
disease 
Guam D. M. Reiff et al., Inherited and somatic mitochondrial DNA mutations in Guam 
amyotrophic lateral sclerosis and parkinsonism-dementia. Neurol Sci 32, 883-892 
(2011). 
mtDNA haplogroup H5 Alzheimer's disease Italy A. Santoro et al., Evidence for sub-haplogroup h5 of mitochondrial DNA as a risk 
factor for late onset Alzheimer's disease. PLoS One 5, e12037 (2010), 
10.1371/journal.pone.0012037. 
mtDNA haplogroups no association with 
Parkinson's disease 
USA D. K. Simon et al., Maternal inheritance and mitochondrial DNA variants in familial 
Parkinson's disease. BMC Med Genet 11, 53 (2010), 10.1186/1471-2350-11-53. 
mtDNA haplogroup H Parkinson's disease UK G. Hudson et al., Two-stage association study and meta-analysis of mitochondrial DNA 
variants in Parkinson disease. Neurology 80, 2042-2048 (2013). 
mtDNA haplogroups J, K, T reduced risk of Parkinson's 
disease 
UK G. Hudson et al., Two-stage association study and meta-analysis of mitochondrial DNA 
variants in Parkinson disease. Neurology 80, 2042-2048 (2013). 
mtDNA haplogroup D 
 
Parkinson's disease China Y. F. Chen et al., Mitochondrial DNA Haplogroups and the Risk of Sporadic 
Parkinson's Disease in Han Chinese. Chin Med J (Engl) 128, 1748-1754 (2015). 
mtDNA haplogroup B 
 
reduced risk of Parkinson's 
disease 
China Y. F. Chen et al., Mitochondrial DNA Haplogroups and the Risk of Sporadic 
Parkinson's Disease in Han Chinese. Chin Med J (Engl) 128, 1748-1754 (2015). 
 
 
mtDNA or Y Chromosome 
Variant 
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Lack of Association) 
Study 
Location Reference 
Neurodegenerative Conditions/Treatment Response (cont.)  
mtDNA haplogroup B5 
 
Alzheimer's disease China R. Bi et al., Mitochondrial DNA haplogroup B5 confers genetic susceptibility to 
Alzheimer's disease in Han Chinese. Neurobiol Aging 36, 1604.e7-16 (2015). 
mtDNA haplogroup L1 Alzheimer's disease USA G. J. Tranah et al., Mitochondrial DNA sequence associations with dementia and 
amyloid-beta in elderly African Americans. Neurobiol Aging 35, 442 e441-448 (2014). 
Opthalmic Diseases/Conditions   
mtDNA 10609C, 10663C  Leber's hereditary optic 
neuropathy 
Kuwait R. Behbehani et al., ND4L gene concurrent 10609T > C and 10663T > C mutations are 
associated with Leber's hereditary optic neuropathy in a large pedigree from Kuwait. 
Brit J Ophthalmol 98, 826-831 (2014). 
mtDNA haplogroups H, R keratoconus Saudi Arabia K.K. Abu-Amero et al., Association of mitochondrial haplogroups H and R with 
keratoconus in Saudi Arabian patients. Invest Ophth Vis Sci 55, 2827-2831 (2014). 
mtDNA haplogroup T increased risk of diabetic 
retinopathy 
Austria B. Kofler et al., Mitochondrial DNA haplogroup T is associated with coronary artery 
disease and diabetic retinopathy: a case control study. BMC Med Genet 10: 35 (2009), 
10.1186/1471-2350-10-35. 
mtDNA 14484C  Leber's hereditary optic 
neuropathy 
Various T. M. Bosley, K. K. Abu-Amero, Assessing mitochondrial DNA nucleotide changes in 
spontaneous optic neuropathies. Ophthalmic Genet 31, 163-172 (2010); N.A. Khan et 
al., Haplogroup heterogeneity of LHON patients carrying the m.14484T > C mutation 
in India. Invest Ophth Vis Sci 54, 3999-4005 (2013). 
mtDNA haplogroup T2 age-related macular 
degeneration 
USA, 
Australia 
J. P. SanGiovanni et al., Mitochondrial DNA variants of respiratory complex I that 
uniquely characterize haplogroup T2 are associated with increased risk of age-related 
macular degeneration. PLoS One 4, e5508 (2009), 10.1371/journal.pone.0005508. 
mtDNA haplogroup L primary open-angle 
glaucoma 
Saudi Arabia K. K. Abu-Amero et al., Mitochondrial DNA lineages of African origin confer 
susceptibility to primary open-angle glaucoma in Saudi patients. Mol Vis 17, 1468-1472 
(2011). 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Opthalmic Diseases/Conditions (cont.)   
mtDNA haplogroup N1 reduced risk of primary 
open-angle glaucoma 
Saudi Arabia K. K. Abu-Amero et al., Mitochondrial DNA lineages of African origin confer 
susceptibility to primary open-angle glaucoma in Saudi patients. Mol Vis 17, 1468-1472 
(2011). 
mtDNA haplogroups L2, T pseudoexfoliation 
glaucoma 
Saudi Arabia K. K. Abu-Amero et al., Eurasian and Sub-Saharan African mitochondrial DNA 
haplogroup influences pseudoexfoliation glaucoma development in Saudi patients. Mol 
Vis 17, 543-547 (2011). 
mtDNA haplogroup N1 reduced risk of 
pseudoexfoliation 
glaucoma 
Saudi Arabia K. K. Abu-Amero et al., Eurasian and Sub-Saharan African mitochondrial DNA 
haplogroup influences pseudoexfoliation glaucoma development in Saudi patients. Mol 
Vis 17, 543-547 (2011). 
mtDNA 11778A  Leber's hereditary optic 
neuropathy 
Various T. M. Bosley, K. K. Abu-Amero, Assessing mitochondrial DNA nucleotide changes in 
spontaneous optic neuropathies. Ophthalmic Genet 31, 163-172 (2010). 
mtDNA 3460A  Leber's hereditary optic 
neuropathy 
Various T. M. Bosley, K. K. Abu-Amero, Assessing mitochondrial DNA nucleotide changes in 
spontaneous optic neuropathies. Ophthalmic Genet 31, 163-172 (2010). 
mtDNA haplogroup B5a1 Leber's hereditary optic 
neuropathy 
Thailand S. Kaewsutthi et al., Mitochondrial haplogroup background may influence Southeast 
Asian G11778A Leber hereditary optic neuropathy. Invest Ophth Vis Sci 52, 4742-4748 
(2011). 
mtDNA haplogroup F reduced risk of Leber's 
hereditary optic 
neuropathy 
Thailand S. Kaewsutthi et al., Mitochondrial haplogroup background may influence Southeast 
Asian G11778A Leber hereditary optic neuropathy. Invest Ophth Vis Sci 52, 4742-4748 
(2011). 
mtDNA haplogroup U reduced risk of exfoliation 
glaucoma 
Germany C. Wolf et al., Mitochondrial haplogroup U is associated with a reduced risk to develop 
exfoliation glaucoma in the German population. BMC Genet 11, 8 (2010), 
10.1186/1471-2156-11-8. 
mtDNA haplogroups A2, C   later onset/reduced impact 
of Leber's hereditary optic 
neuropathy 
Chile 
 
P. Romero et al., Pan-American mDNA haplogroups in Chilean patients with Leber's 
hereditary optic neuropathy. Mol Vis 14, 334-40 (2014). 
mtDNA or Y Chromosome 
Variant 
Proposed Association (or 
Lack of Association) 
Study 
Location Reference 
Opthalmic Diseases/Conditions (cont.)   
mtDNA 14502C, 11778A Leber's hereditary optic 
neuropathy 
China P. Jiang et al., Biochemical evidence for a mitochondrial genetic modifier in the 
phenotypic manifestation of Leber's hereditary optic neuropathy-associated 
mitochondrial DNA mutation. Hum Mol Genet Jul 17. pii: ddw199 (2016). 
mtDNA 3635A, 14502C Leber's hereditary optic 
neuropathy 
China X. Jin et al., Leber's Hereditary Optic Neuropathy is Associated with Compound 
Primary Mutations of Mitochondrial ND1 m.3635G > A and ND6 m.14502 T > C. 
Ophthalmic Genet 36, 291-298 (2015). 
mtDNA 16111, 16362, 16319, 
1736, 12007 
age-related macular 
degeneration 
USA 
 
N. A. Resrepo, et al., Mitochondrial variation and the risk of age-related macular 
degeneration across diverse populations. Pac Symp Biocomput. 243-54 (2015). 
mtDNA haplogroups J, T, U age-related macular 
degeneration 
USA M. C. Kenney et al., Mitochondrial DNA haplogroups confer differences in risk for age-
related macular degeneration: a case control study. BMC Med Genet 14 (2014), 
10.1186/1471-2350-14-4. 
 
 
